What does the licensing of teplizumab mean for diabetes care?-Reference-Cited by-同舟云学术

What does the licensing of teplizumab mean for diabetes care?

Published:2023-04-24 Issue:8 Volume:25 Page:2051-2057
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Quinn Lauren M.¹^ORCID,Swaby Rabbi²,Tatovic Danijela²,Narendran Parth¹³,Besser Rachel E. J.²⁴,Dayan Colin M.²⁵

Affiliation:

1. Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK

2. Wellcome Centre for Human Genetics University of Oxford Oxford UK

3. Department of Diabetes University Hospitals of Birmingham Birmingham UK

4. Department of Paediatrics National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital Oxford UK

5. Diabetes Research Group Cardiff University School of Medicine Cardiff UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference58 articles.

1. FDA. FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes.2022. [January 10 2023]. Available from:https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐first‐drug‐can‐delay‐onset‐type‐1‐diabetes.

2. Preventing type 1 diabetes in childhood

3. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes

4. Type 1 diabetes

5. Beta cells in type 1 diabetes: mass and function; sleeping or dead?

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial;Nature Medicine;2024-07-30